{
    "clinical_study": {
        "@rank": "6623", 
        "arm_group": {
            "arm_group_label": "nab-paclitaxel", 
            "arm_group_type": "Experimental", 
            "description": "nab-paclitaxel (a Taxane class of drug), 100-210 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid\n      tumors, and to see if it works to treat these solid tumors in children and young adults (\u2264\n      21 years old). After the final dose has been chosen, patients will be enrolled according to\n      the specific solid tumor type, (neuroblastoma, rhabdomyosarcoma, or Other solid tumors), to\n      see how nab-paclitaxel works in treating these tumors."
        }, 
        "brief_title": "To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neuroblastoma;", 
            "Rhabdomyosarcoma;", 
            "Ewing's Sarcoma;", 
            "Ewing's Tumor;", 
            "Sarcoma, Ewing's;", 
            "Sarcomas, Epitheliod;", 
            "Sarcoma, Soft Tissue;", 
            "Sarcoma, Spindle Cell;", 
            "Melanoma;", 
            "Malignant Melanoma;", 
            "Clinical Oncology;", 
            "Oncology, Medical;", 
            "Pediatrics, Osteosarcoma;", 
            "Osteogenic Sarcoma;", 
            "Osteosarcoma Tumor;", 
            "Sarcoma, Osteogenic;", 
            "Tumors;", 
            "Cancer;", 
            "Neoplasia;", 
            "Neoplasm;", 
            "Histiocytoma;", 
            "Fibrosarcoma;", 
            "Dermatofibrosarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Histiocytoma", 
                "Neoplasms", 
                "Fibrosarcoma", 
                "Melanoma", 
                "Neuroblastoma", 
                "Osteosarcoma", 
                "Rhabdomyosarcoma", 
                "Sarcoma", 
                "Dermatofibrosarcoma", 
                "Sarcoma, Ewing's"
            ]
        }, 
        "detailed_description": {
            "textblock": "ABI-007-PST-001 is a Phase 1 / 2, multicenter, open-label, dose-finding study to assess the\n      safety , tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric\n      patients with recurrent or refractory solid tumors (excluding brain tumors). The Phase 1\n      portion of the study will be dose escalation design to determine the maximum tolerated dose\n      (MTD) and the recommended Phase 2 dose (RP2D). The Phase 2 portion of the study will enroll\n      additional patients at the RP2D into one of three solid tumor groups [Neuroblastomas,\n      Rhabdomyosarcomas, Other]. Both phases of the study will be open-label and conducted at\n      multiple centers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must meet all of the following criteria to be enrolled in the study:\n\n               1. Patient has a confirmed solid tumor diagnosis according to the following:\n\n                  a. Phase 1:  patient has a recurrent or refractory solid tumor that has\n                  progressed or did not respond to standard therapy, or for which no standard\n                  anticancer therapy exists b. Phase 2:  patient has one of the following tumor\n                  types and has failed first or second-line treatment or has evidence of\n                  refractory disease i. Group 1:  neuroblastoma ii. Group 2:  rhabdomyosarcoma\n                  iii. Group 3:  mixed solid tumors, including nonrhabdomyosarcoma soft tissue\n                  sarcoma, melanoma, or other tumor types identified during the Phase 1 portion or\n                  in preclinical studies\n\n               2. The patient has a Lansky/ Karnofsky performance status score of \u2265 70%\n\n               3. The patient has adequate serum chemistry levels, evidenced by the following\n                  laboratory values a. Aspartate aminotransferase (AST) Serum\n                  glutamic-oxaloacetric transaminase (SGOT), Alanine aminotransferase ALT (Serum\n                  glutamic pyruvate transaminase SGPT) \u2264 2.5 \u00d7 upper limit of normal range (ULN)\n                  b. Total bilirubin \u2264 1.5 \u00d7 ULN c. Creatinine \u2264 1.5 \u00d7 ULN\n\n               4. The patient has adequate bone marrow function, evidenced by the following:\n\n                    1. Absolute neutrophil count \u2265 1.0 \u00d7 109 cells/L\n\n                    2. Platelets \u2265 80 \u00d7 109 cells/L (transfusion independent, defined as not\n                       receiving platelet transfusions within 7 days prior to laboratory sample)\n\n                    3. Hemoglobin \u2265 8 g/dL (transfusion is permitted to fulfill this criterion)\n\n               5. The patient (when applicable) or patient's parent(s) or legal guardian(s)\n                  understand(s) and voluntarily signed an informed consent document prior to any\n                  study-related assessments/procedures being conducted. Where locally applicable,\n                  the patient also understands and voluntarily provides his/her assent prior to\n                  any study-related assessments/procedures being conducted.\n\n               6. Male patients of childbearing potential must use a condom during sexual\n                  intercourse and shall not father a child during the study and for 6 months after\n                  the last dose of study medication.\n\n               7. Female patients of childbearing potential [defined as all female patients \u2265 12\n                  years old or who have reached menarche, whichever occurs first] must have both\n                  of the following:\n\n                  a. Agree to the use of two physician-approved contraceptive methods\n                  simultaneously or practice complete abstinence while on study medication and for\n                  3 months following the last dose of study medication i. True abstinence:  When\n                  this is in line with the preferred and usual lifestyle of the patient. Periodic\n                  abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and\n                  withdrawal are not acceptable methods of contraception.\n\n                  ii. Acceptable contraceptive methods include:  oral, injectable, or implantable\n                  hormonal contraceptive; tubal ligation; intra-uterine device; barrier\n                  contraceptive with spermicide; or vasectomized partner) including at least one\n                  barrier method.\n\n                  b. Have negative serum pregnancy test result at screening confirmed by negative\n                  urine pregnancy dipstick within 72 hours prior to first dose of Investigational\n                  Product (IP) (if serum test occurred > 72 hours from first dose); pregnancy test\n                  with sensitivity of at least 25 mIU/mL.\n\n                  Exclusion Criteria:\n\n                    -  The presence of any of the following will exclude a patient from\n                       enrollment:\n\n               1. The patient has a primary brain tumor(s) or brain metastasis (unless metastasis\n                  is treated and stable for > 28 days). In patients who are symptomatic, a brain\n                  scan is required to exclude metastasis.\n\n               2. The patient has received therapeutic dose chemotherapy or radiotherapy \u2264 21 days\n                  prior to start of Investigational Product.\n\n               3. The patient has received maintenance dose chemotherapy (e.g., low dose\n                  cyclophosphamide) \u2264 7 days from the first dose of Investigational Product.\n\n               4. The patient has received any investigational therapy \u2264 28 days prior to start of\n                  Investigational Product.  Investigational therapy is defined as any medicinal\n                  product that is not approved in the country of treatment for any indication,\n                  adult or pediatric.\n\n               5. The patient has received any biological therapy \u2264 7 days prior to the start of\n                  Investigational Product, or monoclonal antibody \u2264 3 half-lives or 28 days,\n                  whichever is shorter, prior to the first dose of Investigational Product.\n\n          -  6.   The patient has received any hematopoietic stem cell transplantation (HSCT) \u2264 3\n             months prior to start of Investigational Product.\n\n             7. The patient has had major surgery or significant trauma \u2264 14 days prior to start\n             of Investigational Product.\n\n             8. The patient has not recovered from the acute toxic effects of prior chemotherapy,\n             radiation, or major surgery/significant trauma.\n\n             8. The patient has had minor surgery \u2264 7 days from the start of study treatment\n             (excluding the placement of central/peripheral lines, skin biopsy).\n\n             10. The patient has a known history of stroke, myocardial infarction, peripheral\n             vascular disease, or recent (within 3 months) uncontrolled deep venous thrombosis.\n\n             11. The patient has a known history or current diagnosis of human immunodeficiency\n             virus (HIV) infection, regardless of treatment status.\n\n             12. The patient has an uncontrolled intercurrent illness including but not limited to\n             ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy,\n             symptomatic heart failure, cardiac arrhythmia, or psychiatric illness/social\n             situations that would limit compliance with study requirements.\n\n             13. The patient has any significant medical condition, laboratory abnormality, or\n             psychiatric illness that would prevent the patient from participating in the study.\n\n             14. The patient has any condition, including the presence of laboratory\n             abnormalities, that places the patient at unacceptable risk if he/she were to\n             participate in the study.\n\n             15. The patient has any condition that confounds the ability to interpret data from\n             the study.\n\n             16. The patient or parent(s)/guardian(s) is/are unable to comply with the study visit\n             schedule and other protocol requirements, in the opinion of the investigator.\n\n             17.  The patient has \u2265 Grade 2 peripheral neuropathy by National Cancer Institute\n             (NCI) Common Terminology Criteria for Adverse Events (CTCAE) at screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "101", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962103", 
            "org_study_id": "ABI-007-PST-001"
        }, 
        "intervention": {
            "arm_group_label": "nab-paclitaxel", 
            "description": "nab-paclitaxel (a Taxane class of drug), 100-210 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle.", 
            "intervention_name": "nab-paclitaxel", 
            "intervention_type": "Drug", 
            "other_name": "Abraxane"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Neuroblastoma, Rhabdomyosarcoma, Soft Tissue; Pediatric Oncology, Abraxane, albumin-bound paclitaxel, nab-paclitaxel, ABI-007, taxane, solid tumors", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85016"
                    }, 
                    "name": "Phoenix Children's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 1X8"
                    }, 
                    "name": "The Hospital for Sick Children"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69008"
                    }, 
                    "name": "Institute for Pediatric Hemato-Oncology, Leon Berard Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nancy", 
                        "country": "France", 
                        "zip": "54000"
                    }, 
                    "name": "H\u00f4pital d'Enfants, CHU Nancy"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75005"
                    }, 
                    "name": "Institut Curie"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Institut Gustave Roussy"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "zip": "16147"
                    }, 
                    "name": "Children's Hospital Largo"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20133"
                    }, 
                    "name": "Istituto Nazionale Tumori"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "zip": "35128"
                    }, 
                    "name": "Clinica di Oncoematologia"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "zip": "10126"
                    }, 
                    "name": "l'Azienda Ospedaliera Regina Margherita - Sant Anna"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Universitario Vall D`Hebron"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28029"
                    }, 
                    "name": "Spanish National Cancer Research Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "Unidad de Oncologia Pediatrica, Hospital Universitario la Fe"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "8032"
                    }, 
                    "name": "Universit\u00e4ts-Kinderklinik"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "zip": "Sm2 5PT"
                    }, 
                    "name": "Royal Marsden Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "France", 
                "Italy", 
                "Spain", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 / 2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors", 
        "overall_contact": {
            "email": "clinicaltrialdisclosure@celgene.com", 
            "last_name": "Associate Director Clinical Trial Disclosure", 
            "phone": "1-888-260-1599"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Ileana Elias, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du Medicament et des produits de sant\u00e9", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Switzerland: Swissmedic. Swiss Agency for Therapeutic Products", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of patients with a DLT", 
                "measure": "Incidence of Dose Limiting Toxicities (DLT) (Phase 1)", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 98 days"
            }, 
            {
                "description": "Number of patients with adverse events", 
                "measure": "Incidence of adverse events (Phase 1)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Number of patients with Complete response (CR) or partial response (PR) based on investigator assessment of response using RECIST 1.1 guidelines", 
                "measure": "Overall response rate (ORR) (Phase 2)", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962103"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maximum observed concentration in blood plasma", 
                "measure": "Pharmacokinetics (PK) - Cmax (Phase 1)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4"
            }, 
            {
                "description": "Area under the plasma concentration-time curve", 
                "measure": "Pharmacokinetics (PK) - AUC (Phase 1)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4"
            }, 
            {
                "description": "Measurement of renal clearance from the body", 
                "measure": "Pharmacokinetics (PK) - Clearance (Phase 1)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4"
            }, 
            {
                "description": "Volume of distribution", 
                "measure": "Pharmacokinetics (PK) - Vss (Phase 1)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4"
            }, 
            {
                "description": "Number of patients with Complete response (CR) or partial response (PR) based on investigator assessment of response using RECIST 1.1 guidelines", 
                "measure": "Overall Response Rate (ORR) (Phase 1)", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Time from complete response (CR) or partial response (PR) [whichever is first recorded] until the date that progression-free survival event is documented", 
                "measure": "Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "The percentage of patients with a confirmed objective CR or PR, or stable disease for at least 16 weeks", 
                "measure": "Disease Control Rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Time from the start of treatment until the first progression or death by any cause, according to RECIST 1.1 guidelines", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Time from the start of treatment until death by any cause", 
                "measure": "1-year survival", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 2 years"
            }, 
            {
                "description": "Number of participants with adverse events", 
                "measure": "Safety", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Maximum observed concentration in blood", 
                "measure": "Pharmacokinetics (PK) -Cmax (Phase 2)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4"
            }, 
            {
                "description": "Area under the plasma concentration-time curve", 
                "measure": "Pharmacokinetics (PK) - AUC (Phase 2)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4"
            }, 
            {
                "description": "Measurement of renal clearance from the body", 
                "measure": "Pharmacokinetics (PK) - Clearance (Phase 2)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4"
            }, 
            {
                "description": "Volume of distribution from both Phase 1 and Phase 2", 
                "measure": "Pharmacokinetics (PK) - Vss (Phase 2)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}